Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined pursuant to the first inventor to file provisions of the AIA .
DETAILED ACTION
Status of the Claims
Applicants filed claims 1 – 15 with the instant application on 21 March 2025. Currently, claims 1 – 15 remain available for substantive consideration.
Information Disclosure Statement
The Examiner has considered the information disclosure statement (IDS) filed 30 September 2025, which is now of record in the file.
Rejections Pursuant to 35 U.S.C. § 103
The following is a quotation of 35 U.S.C. § 103 that forms the basis for all obviousness rejections set forth in this Office Action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the Examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention absent any evidence to the contrary. Applicants are advised of the obligation pursuant to 37 CFR § 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the Examiner to consider the applicability of 35 U.S.C. § 102(b)(2)(C) for any potential 35 U.S.C. § 102(a)(2) prior art against the later invention.
Claims 1 – 15 are rejected pursuant to 35 U.S.C. § 103, as being obvious over US 2018/0228857 A1 to Toh, J., et al., published 16 August 2018, identified in the Information Disclosure Statement (IDS) filed 30 September 2025, cite no. 018 (“Toh ‘857”), in view of US 2003/0219472 A1 to Pauletti, G., et al., published 27 November 2023, identified in the IDS filed 30 September 2025, cite no. 010 (“Pauletti ‘472”).
The Invention As Claimed
Applicants claim a method of preventing or treating an allergic disease or condition in a subject in need thereof, comprising administering a therapeutically effective amount of a sprayable aqueous intranasal composition to the subject's mucosa, wherein the composition forms a barrier on the mucosa, wherein the sprayable aqueous intranasal composition comprises about 0.1 % to about 0.8% by weight of a mucoadhesive polymer/xanthan gum, about 1.7% to about 2.8% by weight of a clay/bentonite, about 30% to about 40% by weight of caprylic/capric triglycerides, and one or more chelating agents/Na2EDTA, wherein the composition has no more than 0.5% by weight of preservatives, and wherein the composition is thixotropic, wherein the allergic disease or condition is caused by, or exacerbated by, airborne allergens such as pollens, dust mites, molds, animal dander, and/or spores, wherein the allergic disease or condition is one or more of rhinitis, sinusitis, asthma, hypersensitive pneumonia, extrinsic allergic alveolitis, conjunctivitis, urticaria, eczema, dermatitis, anaphylaxis, angioedema, allergic, and migraine headache, wherein the clay is bentonite, wherein the mucoadhesive polymer is sodium alginate, chitosan, guar gum, xanthan gum, pectin, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, poly( ethylene oxide), poly(acrylic acid), poloxamer, blends of microcrystalline cellulose, sodium carboxymethyl cellulose, or combinations thereof, wherein the sprayable aqueous intranasal composition is free of preservatives, wherein the sprayable aqueous intranasal composition further comprises one or more antioxidants, wherein the one or more chelating agents of the sprayable aqueous intranasal composition comprises disodium EDTA, wherein the pH of the composition is about 4 to about 7, or about 5 to about 6.8, wherein the sprayable aqueous intranasal composition further comprises about 3% to about 7% by weight of a moisturizing agent comprising glycerin, ethylene glycol, propylene glycol, propylene glycol 400, polyethylene glycol 400, hexalene glycol, butylene glycol, dextrose, glyceryl triacetate, polydextrose, glycerol, glyceryl triacetate, sorbitol, mannitol, or combinations thereof, wherein, after spraying about 50 µL to about 200 µL of the composition to the nasal mucosa of a subject, the composition is retained on the nasal mucosa for about 20 minutes to about 5 hours, and wherein the sprayable aqueous intranasal composition comprises about 1.7% to about 2.8% by weight of bentonite, about 30% to about 40% by weight of caprylic/capric triglycerides, about 0.1 % to about 0.8% by weight of xanthan gum, butylated hydroxyanisole, disodium EDTA, wherein the pH of the composition is about 4 - 7.
The Teachings of the Cited Art
Toh ‘857 discloses oil-based nasal compositions comprising a barrier-forming preparation useful for treating disorders of the nasal cavity, such as rhinitis (see Abstract), wherein the compositions are designed to treat or prevent allergic disorders of the nasal cavity, such as allergic rhinitis, including pollinosis (see ¶[0008]), wherein the compositions are sprayable, resulting in an enhanced efficacy in prophylaxis and treatments of allergic disorders of the nasal cavity, including seasonal allergic rhinitis and perennial allergic rhinitis (see ¶[0009]; see also ¶[0026]), wherein use of the disclosed compositions aims to inhibit mast cell activation and/or mast cell degranulation and/or release of histamine from mast cells (see ¶[0010]), wherein the barrier-forming preparation comprises an oily component, one or more gel formers for a thixotropic gel, and an aqueous base (see ¶[0014]), wherein the gel-formers comprise xanthan gum and/or bentonite (see ¶[0017]), wherein the aqueous base comprises water, or water with stabilizing additives (see ¶[0018]), wherein the barrier preparation is an oil-in-water emulsion (see ¶[0019]), wherein the nasal composition can be prepared in the form of a nasal spray (see ¶[0020]), wherein the compositions comprise pharmaceutically excipients, such as binders, surfactants, preservatives, colorants, flavoring substances, pH regulators, regulators of osmotic activity, and salt-forming groups (see ¶[0022]), wherein the compositions are considered to be thixotropic preparations means that the preparations, when subjected to shear forces (shaking, pressing through a nozzle, stirring, or the like), a low viscosity (sol state), are suitable in particular for use in particular as a nasal spray (see ¶[0041]), wherein the barrier-forming preparation is capable of providing a positive effect against nasal disorders, in particular allergic rhinitis, by providing a “mechanical” barrier on nasal membranes, based on a blocking effect against allergens, in particular due to the oily components and/or the viscosity of the gel, the allergens being no longer able to proliferate directly on the nasal mucous membrane due to the largely uniform distribution of the gel composition on the mucous membrane (see ¶[0046]), wherein examples of oily components that can be used in the compositions comprise animal oils, saturated or non-saturated esters, higher alcohols and/or silicone oils, or mixtures of two or more of these components (see ¶[0057]), wherein the oily component contributes to the thixotropic properties of the formulations (see ¶[0058]), wherein the oily component is present in the formulations from about 10 to about 80% wgt (see ¶[0059]; see also ¶[0063]), wherein the gel formers are responsible for formulating the compositions as a thixotropic gel, and the thixotropic gel provides the effect of creating suspensions, enhancing thixotropic properties (see ¶[0065]), wherein the gel formers for nasal compositions include kaolin clays forming colloids, in particular metal oxide silicates, such as bentonite (see ¶[0067]), wherein the compositions contain xanthan gum and/or bentonite as the main gel-forming components for the thixotropic gel (see ¶[0069]), wherein the gel formers are present in the compositions at loadings of from about 0.1 to about 15% wgt (see ¶[0070]), wherein the aqueous base of the compositions comprises water and water-soluble additives, such as 1,2-propylene glycol or glycerine (see ¶[0072]), wherein the 1,2-propylene glycol is present in the compositions at loadings from about 0.1 to 10% wgt (see ¶[0073]), wherein the formulations are in the form of nasal sprays (see ¶[0077]), wherein a portable spray device that can be activated manually by finger pressure is used for the nasal spray (see ¶[0078]), wherein, upon use of the spray device, sprayed droplets will come into contact with the nasal mucosa to form a gel barrier that covers substantially the entire surface area of the nasal cavity providing a substantially complete coverage to the nasal cavity against airborne allergens on the surface (see ¶[0081]), wherein a pharmaceutically acceptable carrier, excipient and/or diluent for use in the composition are selected from binders, surfactants, preservatives, colorants, flavoring substances, pH regulators, regulators of the osmotic activity and salt-forming groups (see ¶[0085]), wherein preservation agents include butylated hydroxyanisole (BHA) and/or EDTA, present at loadings of from 0.5 to about 5% wgt (see ¶[0088]), wherein phosphate or citrate buffer systems may be used to regulate pH to a range between 3 and 9 (see ¶[0091]), wherein the compositions comprise a preservation agent such as EDTA (see ¶[0094]), wherein the compositions are useful in preventing and/or treating disorders of the nasal cavity because they are able to form a mechanical barrier on nasal mucosa, which is impermeable to common allergens such as pollens, animal dander and dust mites, the barrier being formed due to the thixotropic properties of the emulsion containing mucoadhesive gel-forming ingredients (such as xanthan gum and/or bentonite), the impermeable gel layer blocking contact between incoming allergen particles and nasal mucosa, thereby preventing the trigger of allergic reaction and stopping the onset of allergic rhinitis symptoms (see ¶[0106]), wherein the compositions are used in a method for preventing and/or treating allergic disorders of the nasal cavity, including seasonal allergic rhinitis and perennial allergic rhinitis, in a subject comprising the step of administering to the subject an effective amount of the disclosed nasal composition (see ¶[0109]), wherein administration of the spray composition takes place once or several times daily, at intervals of a few hours, for example at intervals of about 1 to 8 hours and, in particular, of about 4 to 6 hours (see ¶[0111]), and wherein subjects to receive administration of the compositions comprise mammals, including humans (see ¶[0113]). The reference does not expressly disclose use of a sprayable composition comprising 30% to about 40% by weight of caprylic/capric triglycerides, or Na2EDTA, or a moisturizing agent at 3 – 7% wgt. These deficiencies are remedied by the teachings of Pauletti ‘472.
Pauletti ‘472 discloses compositions and methods for vaginal, buccal or nasal transmucosal delivery of drugs, the compositions consisting essentially of a non-ionizable glycol derivative in combination with a pharmaceutically active agent, wherein for transmucosal delivery, the non-ionizable glycol derivative may be further combined with a mucoadhesive agent and/or a penetration enhancer and/or lipophilic or hydrophilic carrier for adhesion to and transport through a mucosa (see Abstract), wherein the compositions promote effective transmucosal delivery of pharmaceutical agents through nasal, buccal or vaginal mucosa into systemic blood circulation (see ¶[0017]), wherein the compositions consist essentially of about 0.01 to about 60% of a non-ionizable glycol, the compositions formulated as a solution incorporated into a device for insertion into the nasal cavity (see ¶[0021]), wherein preferred lipophilic carriers for use with hydrophilic drugs include non-ionizable glycols in the form of mixtures of triglycerides of higher saturated fatty acids, particularly fatty acids from C8 to C18 carbon backbones (see ¶[0064]), such as mixtures of caprylic and capric triglycerides (see ¶[0053]; see also claim 2), wherein the compositions may also comprise a mucoadhesive agent to bring the drug into prolonged, close contact with the mucosal surface (see ¶[0066]), wherein the compositions are incorporated into a gel, or other form, suitable for nasal spray application (see ¶[0069]), wherein the compositions comprise between about 0.05 - 25% of a mucoadhesive agent, and, optionally, between about 5 - 10% of an absorption promoter, solubilizer or another pharmaceutically acceptable excipient (see ¶[0070]), and wherein, for nasal transmucosal administration, the compositions are formulated as spray formulations (see ¶[0140]).
Application of the Cited Art to the Claims
It would have been prima facie obvious before the filing date of the claimed invention to use oil-based nasal compositions comprising a barrier-forming preparation useful for treating disorders of the nasal cavity, such as rhinitis, wherein the compositions are designed to treat or prevent allergic disorders of the nasal cavity, wherein the compositions are sprayable, wherein the barrier-forming preparation comprises an oily component, one or more gel formers for a thixotropic gel, and an aqueous base, wherein the gel-formers comprise xanthan gum and/or bentonite, wherein the aqueous base comprises water with stabilizing additives, wherein the nasal composition can be prepared in the form of a nasal spray, wherein the compositions are considered to be thixotropic preparations because that means that the preparations, when subjected to shear forces (shaking, pressing through a nozzle, stirring, or the like), a low viscosity (sol state), are suitable for use in particular as a nasal spray, wherein the barrier-forming preparation is capable of providing a positive effect against nasal disorders, in particular allergic rhinitis, by providing a “mechanical” barrier on nasal membranes, based on a blocking effect against allergens, in particular due to the oily components and/or the viscosity of the gel, the allergens being no longer able to proliferate directly on the nasal mucous membrane due to the largely uniform distribution of the gel composition on the mucous membrane, wherein examples of oily components that can be used in the compositions comprise animal oils, saturated or non-saturated esters, higher alcohols and/or silicone oils, or mixtures of two or more of these components, wherein the oily component is present in the formulations from about 10 to about 80% wgt, wherein the gel formers are responsible for formulating the compositions as a thixotropic gel, and the thixotropic gel provides the effect of creating suspensions, and enhancing thixotropic properties, wherein the gel formers for nasal compositions include kaolin clays forming colloids, in particular metal oxide silicates, such as bentonite, wherein the compositions contain xanthan gum and/or bentonite as the main gel-forming components for the thixotropic gel, wherein the gel formers are present in the compositions at loadings of from about 0.1 to about 15% wgt, wherein the aqueous base of the compositions comprises water and water-soluble additives, such as 1,2-propylene glycol or glycerine, wherein the 1,2-propylene glycol is present in the compositions at loadings from about 0.1 to 10% wgt, wherein the formulations are in the form of nasal sprays delivered from a portable spray device that can be activated manually by finger pressure, wherein a pharmaceutically acceptable carrier, excipient and/or diluent for use in the composition are selected from binders, surfactants, preservatives, colorants, flavoring substances, pH regulators, regulators of the osmotic activity and salt-forming groups, wherein preservation agents include butylated hydroxyanisole (BHA) and/or EDTA, present at loadings of from 0.5 to about 5% wgt, wherein phosphate or citrate buffer systems may be used to regulate pH to a range between 3 and 9, wherein the compositions comprise a preservation agent such as EDTA, wherein the compositions are useful in preventing and/or treating disorders of the nasal cavity because they are able to form a mechanical barrier on nasal mucosa, which is impermeable to common allergens such as pollens, animal dander and dust mites, the barrier being formed due to the thixotropic properties of the emulsion containing mucoadhesive gel-forming ingredients (such as xanthan gum and/or bentonite), the impermeable gel layer blocking contact between incoming allergen particles and nasal mucosa, thereby preventing the trigger of allergic reaction and stopping the onset of allergic rhinitis symptoms (see ¶[0106]), wherein the compositions are used in a method for preventing and/or treating allergic disorders of the nasal cavity, including seasonal allergic rhinitis and perennial allergic rhinitis, in a subject comprising the step of administering to the subject an effective amount of the disclosed nasal composition, wherein administration of the spray composition takes place once or several times daily, at intervals of a few hours, for example at intervals of about 1 to 8 hours and, in particular, of about 4 to 6 hours, and wherein subjects to receive administration of the compositions comprise mammals, including humans, as taught by Toh ‘857, and wherein the compositions consisting essentially of a non-ionizable glycol derivative in combination with a pharmaceutically active agent, wherein the compositions consist essentially of about 0.01 to about 60% of a non-ionizable glycol, the compositions formulated as a solution incorporated into a device for insertion into the nasal cavity, wherein preferred lipophilic carriers for use with hydrophilic drugs include non-ionizable glycols in the form of mixtures of triglycerides of higher saturated fatty acids, particularly fatty acids from C8 to C18 carbon backbones, such as mixtures of caprylic and capric triglycerides, as taught by Pauletti ‘472. One of skill in the art would be motivated to do so, with a reasonable expectation of success in so doing, by the express teachings of Pauletti ‘472 to the effect that the oil component (capric/caprylic acid triglycerides) is largely responsible for the blocking effect of the compositions when sprayed on the mucosal surfaces of the nasal cavity, and which prevent the actions of allergens.
With respect to claim 2, which claim recites a limitation directed to the cause of the diseases being treated according to the disclosed method being airborne allergens, the Examiner notes that Toh ‘857 specifically teaches, at ¶[0008], that the disclosed compositions are useful in treating or preventing the effects of pollinosis (hay fever), which condition one of ordinary skill in the relevant art would recognize from nasal ingestion of common allergens, such as pollen, thus meeting this limitation.
With respect to claim 10, which claim recites a limitation directed to the chelating agent in the compositions used in the method of the invention being disodium EDTA, the Examiner notes that Toh ‘857 discloses compositions comprising EDTA, which the skilled artisan would recognize as the fully protonated form of EDTA. However, in the claimed pH range of the compositions (about 4 to about 7), that skilled artisan would also appreciate that the EDTA molecule would be in a dianionic form (two protons dissociated), which form is the form of EDTA in disodium EDTA. Consequently, it is the Examiner’s position that it would be prima facie obvious to use disodium EDTA in compositions comprising EDTA, particularly in solutions with a pH approaching 7.0.
With respect to those claims reciting ranges of quantitative values (see claims 1, 13, and 15), the Examiner notes that the cited at does not expressly disclose quantitative ranges exactly congruent with the claimed ranges. However, it is the Examiner’s position that the cited art discloses quantitative ranges that significantly overlap with the claimed ranges and, as such, would render the claimed invention obvious. See MPEP § 2144.05. “In the case where the claimed ranges ‘overlap or lie inside ranges disclosed by the prior art’ a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976).”
Claims 14 and 15 recite limitations directed to the period of time that the composition of the invention, once sprayed onto the mucosal surfaces of the nasal cavity, would be retained. In this regard, the Examiner notes that, although the cited references do not expressly disclose a retention period, Toh ‘857 teaches that the disclosed compositions are applied several times daily, at intervals of about 1 to 8 hours or, in particular, of about 4 to 6 hours (see ¶[0111]). It is the Examiner’s position, therefore, that the typical application frequency would be reflective of the compositions being retained on the nasal mucosa for a period of time reading on the recited interval of 20 minutes to 5 hours.
In light of the forgoing discussion, the Examiner concludes that the subject matter defined by claims 1 – 15 would have been obvious within the meaning of 35 USC § 103.
NO CLAIM IS ALLOWED.
CONCLUSION
Any inquiry concerning this communication or any other communications from the examiner should be directed to Daniel F. Coughlin whose telephone number is (571)270-3748. The examiner can normally be reached on M-F 8:30 am - 5:30 pm.
If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor, David J Blanchard, can be reached on (571)272-0827. The fax phone number for the organization where this application or proceeding is assigned is (571)273-8300.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/-interviewpractice.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/DANIEL F COUGHLIN/
Examiner, Art Unit 1619
/DAVID J BLANCHARD/ Supervisory Patent Examiner, Art Unit 1619